Cargando…

Potential (18)F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy

PURPOSE: To investigate the ability of potential imaging biomarkers based on (18)F-AlF-NOTA-PRGD2 positron emission tomography/computed tomography ((18)F-RGD PET/CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) imaging to predict the response to bevacizumab combined with conven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Liu, Ning, Zhang, Hui, Tao, Rongjie, Zhao, Shuqiang, Chen, Zhaoqiu, Fu, Zheng, Li, Wanhu, Xu, Liang, Liu, Yuhui, Yu, Jinming, Yuan, Shuanghu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459034/ https://www.ncbi.nlm.nih.gov/pubmed/36091179 http://dx.doi.org/10.3389/fonc.2022.848266

Ejemplares similares

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors
por: Li, Li, et al.
Publicado: (2022)

(18)F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer
por: Li, Li, et al.
Publicado: (2020)

Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis
por: Wang, Xiaoyue, et al.
Publicado: (2017)

Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma
por: Liu, Changmin, et al.
Publicado: (2020)

Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Liu, Jie, et al.
Publicado: (2019)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment
por: Xue, Wei, et al.
Publicado: (2017)

GPU-Accelerated Compartmental Modeling Analysis of DCE-MRI Data from Glioblastoma Patients Treated with Bevacizumab
por: Hsu, Yu-Han H., et al.
Publicado: (2015)

Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
por: De Bruyne, S, et al.
Publicado: (2012)

Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages
por: Li, Guanzhang, et al.
Publicado: (2019)

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
por: Darmon, Ilan, et al.
Publicado: (2017)

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

(18)F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer
por: Luan, Xiaohui, et al.
Publicado: (2016)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

(18)F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment
por: Liu, Jie, et al.
Publicado: (2021)

Tumor angiogenesis at baseline identified by (18)F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Wei, Yuchun, et al.
Publicado: (2022)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

(18)F-Fluorothymidine PET-CT for Resected Malignant Gliomas before Radiotherapy: Tumor Extent according to Proliferative Activity Compared with MRI
por: Zhao, Fen, et al.
Publicado: (2015)

Internalisation of RGD-Engineered Extracellular Vesicles by Glioblastoma Cells
por: Gečys, Dovydas, et al.
Publicado: (2022)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

PET imaging of (68)Ga-NODAGA-RGD, as compared with (18)F-fluorodeoxyglucose, in experimental rodent models of engrafted glioblastoma
por: Isal, Sibel, et al.
Publicado: (2018)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Negative Correlation Between (18)F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer
por: Wu, Leilei, et al.
Publicado: (2022)

A Pilot Study of (18)F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer
por: Zhou, Yue, et al.
Publicado: (2017)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

Response Prediction to Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Delta-Radiomics Based on Sequential Whole-Tumor ADC Map
por: An, Dianzheng, et al.
Publicado: (2022)

Understanding DCE /
por: Rosenberry, Ward
Publicado: (1992)

A Comparative Study of Noninvasive Hypoxia Imaging with (18)F-Fluoroerythronitroimidazole and (18)F-Fluoromisonidazole PET/CT in Patients with Lung Cancer
por: Wei, Yuchun, et al.
Publicado: (2016)

BIMG-06. RESPONSE ASSESSMENT OF BEVACIZUMAB THERAPY FOR GLIOBLASTOMA BY USING MULTIPLE PET TRACERS
por: Miyake, Keisuke, et al.
Publicado: (2021)

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma
por: Takigawa, Kosuke, et al.
Publicado: (2021)

Recurrence patterns are significantly associated with the (18)F‑FDG PET/CT radiomic features of patients with locally advanced non‑small cell lung cancer treated with chemoradiotherapy
por: Liu, Wenju, et al.
Publicado: (2023)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy
por: Mapelli, Roberto, et al.
Publicado: (2021)

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
por: Poulsen, Sidsel Højklint, et al.
Publicado: (2016)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ei5e31jsffci06s1iillukm5rf